-
Reminder of the risks of chloroquine and hydroxychloroquine
Reminder of the risks of chloroquine and hydroxychloroquine
-
Reminder of the risks of chloroquine and hydroxychloroquine
Reminder of the risks of chloroquine and hydroxychloroquine
EMA is reminding healthcare professionals to closely monitor patients with COVID-19 who are receiving chloroquine or hydroxychloroquine, given the serious side effects that can result from treatment with these medicines.
-
CHMP highlights: May 2020
CHMP highlights: May 2020
-
CHMP highlights: May 2020
CHMP highlights: May 2020
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its 25-28 May meeting.
-
European medicines regulatory network fully mobilised in fight against COVID-19
European medicines regulatory network fully mobilised in fight against COVID-19
-
European medicines regulatory network fully mobilised in fight against COVID-19
European medicines regulatory network fully mobilised in fight against COVID-19
EMA, together with EU Member States and the European Commission, has published a plan outlining principles for how the network will ensure that core public and animal health regulatory activities, such as the authorisation, maintenance and supervision of human and veterinary medicines will continue to be carried out during the ongoing COVID-19 pandemic.
-
COVID-19: latest updates
COVID-19: latest updates
-
COVID-19: latest updates
COVID-19: latest updates
Keep up to date with the latest information from EMA on the COVID-19 pandemic.
